Quoin Pharmaceuticals Ltd - ADR
QNRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.94M
Close$
$27.05
490.5% upside
Current Fair Value
490.5% upsideUndervalued by 490.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.94 Million |
|---|---|
| Enterprise Value | $5.81 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-10.63 |
| Beta | 1.68 |
| Outstanding Shares | 2,830,970 |
Return
| Return on Equity | -180161.89% |
|---|---|
| Return on Assets | -100719.75% |
| Return on Invested Capital | -36.46% |
Valuation & Multiples
| P/E Ratio | -0.25 |
|---|---|
| PEG | -0.81 |
| Price to Sales | - |
| Price to Book Ratio | 1.53 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.54 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-1.99
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-1.61
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 60.41%▲ 4.16% |
|---|---|
| Total Invested | $7.82M▼ 35.71% |
| Investors Holding | 20▲ 2.00% |
ESG Score
No data
About Quoin Pharmaceuticals Ltd
2,020 employeesCellect Biotechnology has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.